MaxCyte Inc (NAS:MXCT)
$ 4.24 0.08 (1.92%) Market Cap: 432.15 Mil Enterprise Value: 293.28 Mil PE Ratio: 0 PB Ratio: 1.94 GF Score: 79/100

MaxCyte Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 02:50PM GMT
Release Date Price: $5.89
Max Masucci
Cowen and Company - Analyst

[Welcome to the] 42nd Annual Cowen Healthcare Conference. I am Max Masucci, life science and diagnostic tools analyst at Cowen. It's my pleasure to welcome MaxCyte, a market-leading nonviral cell engineering company, a critical enabler of the cell therapy field. We are pleased to be joined by President and CEO, Doug Doerfler; and Amanda Murphy will be joining shortly. Good to see you, Doug.

Doug Doerfler
MaxCyte, Inc. - President & CEO

Max, good to see you too. Thank you very much. Happy Monday morning.

Questions & Answers

Max Masucci;Doug Doerfler<
Cowen and Company - Analyst

Yes, yes, absolutely. We're off and running. Starting off with just a standard question that we're asking a lot of companies this week, including those that serve a global customer, base, are you seeing any ripple effect in the European customer base from the ongoing situation in Ukraine? Is there any exposure there, whether it's from a customer supply chain perspective?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot